medical device investing Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
medical device investing Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
medical device investing Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
medical device investing Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
medical device investing Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
medical device investing Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
medical device investing Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
medical device investing Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
medical device investing Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
medical device investing A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
medical device investing A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
medical device investing A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
medical device investing Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
medical device investing Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Apex Extends Trinity Zone 200 m with 3.55% REO over 116.0 m and 2.35% over 171.5 m in Western Step-out Drilling at Rift
Goldera Expands High-Grade E1 Gold Discovery with Two New Parallel Structures Ahead of Planned Q4 Drilling at Egan Gold Project
Oreterra CEO Letter to Shareholders Provides Forward Guidance on Trek South Drill Results in Advance of Assays
LaFleur Minerals Intersects 6.05 g/t Au over 8.00 Metres, Including 14.96 g/t Au over 3.00 Metres, Near Surface at Bartec Target and Identifies Additional New Targets at the Swanson Property
